Warts are very common benign epithelial tumors caused by human papillomaviruses (HPVs), a large family of small, non-enveloped, double-stranded DNA viruses. More than 180 different types of HPVs have been sequenced. The HPV type involved, the affected anatomical location and the immune status of the host determines the clinical manifestation of the warts which may present as common, plane, plantar, filiform or digitate, myrmecia, mosaic, genital, and periungual warts. There is no consensus for the definition of recalcitrant warts, but it is generally described as warts that persist for more than six months after failure of at least five treatment sessions. Most people seek treatment for facial warts as they are cosmetically disfiguring. Many topical, destructive, and immunotherapeutic modalities are available for treatment but none is 100% effective. Recently, intralesional antigen immunotherapy has shown promising efficacy and tolerance in the treatment of warts including the facial ones. We report two cases of recalcitrant facial warts presented during 2019. Both cases was completely resolved.
with a single intralesional injection of the Measles-Mumps-Rubella (MMR) vaccine.

**CASE REPORTS**

**Case one**
A healthy 38-year-old Omani male presented to the Dermatology Clinic at Nizwa Polyclinic, Oman, with eight months history of asymptomatic skin lesions over his chin and neck. These had increased after several visits to the barbershop during which razors were used for shaving. The examination showed numerous (about 60) flat-topped and verrucous papules over the submandibular area of the neck [Figure 1a]. Before presentation, he underwent six sessions of cryotherapy at a private dermatology center which resulted in clearance, but the lesions kept recurring. A clinical diagnosis of common and filiform warts was made. Treatment with intralesional MMR was suggested, to which he agreed verbally. We injected 0.2 ml of the MMR vaccine into the two biggest warts. No complications were reported apart from mild temporary pain during the injection. No adjunctive treatment was used. On follow-up after two weeks, the facial warts had cleared completely [Figure 1b], and on subsequent follow-ups after two and six months, there was no recurrence.

**Case two**
A 42-year-old man presented to the dermatology clinic at Nizwa Polyclinic with one-year history of a papular eruption on his face. He attributed the eruption to a recent barbershop visit. He had previously been unsuccessfully treated with imiquimod cream, cryotherapy, and electrocautery. He had no co-morbidities and was not using any oral medications. The examination showed multiple (about 40), tiny, and grouped monomorphic papules bilaterally distributed over the mental area of the face [Figure 2a]. A clinical diagnosis of recalcitrant cutaneous warts was made. Treatment with intralesional MMR vaccine was offered, to which he agreed. We injected 0.1 ml of the MMR vaccine into the biggest papule bilaterally. No other treatment was given. Follow-up after one month showed complete resolution [Figure 2b], and further follow-up after three months showed no recurrence. No complications were reported.

**DISCUSSION**
Viral warts are highly contagious and can spread via direct skin contact, especially if there are predisposing factors like skin maceration. In our cases, the cause might be attributed to contamination at the barbershop. Many men in Oman visit barbershops weekly for beard trimming and shaving. Proper sanitation is uncertain at these places, which raises a public health concern. Local spreading of pre-existing warts (pseudo-koebnerization) is common after hair removal methods involving skin breach; therefore, instead of razors, electric trimmers are suggested for men with existing facial warts, who should also refrain from touching their warts to
minimize the spread to other parts of the body and to other people.

Many modalities for treatment have been reported for facial warts including topicals, systemic medications, destructive methods, and intralesional immunotherapy. Imiquimod cream, approved by Food and Drug Administration for genital warts, has also been used effectively for facial warts, especially the plane ones. Its disadvantages include the risk of post-inflammatory hyperpigmentation (PIH) and high cost. Clouth et al. reported sinecatechins ointment which has minimal side effects. Topical cantharidin, a vesicant produced by beetles in the order Coleoptera, is another option, but has the risk of PIH, especially in skin types 3 to 5, and scarring.

Oral isotretinoin, a retinoid used primarily for severe acne, is also reported to be effective for recalcitrant facial plane warts (fixed dose of 30 mg/day or a mean dose of 0.5 mg/kg/day for at least 12 weeks). Drawbacks include the prolonged treatment period, side effects like cheilitis and dry eyes, as well as the need for monitoring lipid profile and liver function.

Laser and light therapies are also used to treat recalcitrant facial warts. Pulsed dye laser at 585 nm wavelength has high clearance rates. This option is limited by cost, the requirement of multiple visits, and pain. Yttrium aluminum garnet laser is a single-session treatment option, but is expensive and carries the risks of scarring and PIH. Intralesional 2% zinc sulfate solution is another uncommon treatment, but needs special preparation and can cause cosmetically unacceptable textural changes.

Intralesional immunotherapy by different agents like the MMR vaccine, Candida albicans antigen, purified protein derivative (PPD) vaccine, and Bacillus Calmette–Guérin vaccine have gained recent attention for treating warts, including the recalcitrant ones. Among them, PPD and MMR are considered as the most effective modalities for lesion clearance at primary and distant sites and also reduce recurrence. The mechanism of intralesional immunotherapy is still unknown but is reportedly associated with the release of immunoregulatory cytokines such as interleukins-2 and 12, interferon α, and tumor necrosis factor-α, which stimulate strong immune response against HPV.

In an open-label study, Nofal et al. studied intralesional injection with 0.3 mL MMR vaccine for 65 patients with recalcitrant warts, 41 (63%) had a complete response, and 2 had a recurrence. In another single-blinded randomized clinical trial by Awal et al. for common warts, the complete response was 68%. In both studies, most patients required rate more than one session. However, it is not stated how many among them had facial warts and their response rates. Temporary pain during the injection is the commonest side effect reported (as in our cases), other less frequently reported ones include flu-like symptoms, itching, erythema, and edema.

Regarding our two cases, both patients had complete response by a single intralesional injection of the MMR vaccine without any adjunctive treatment. However, further randomized clinical trials are needed to study the efficacy of intralesional MMR for patients with numerous recalcitrant facial warts.

CONCLUSION
Intralesional immunotherapy with the MMR vaccine seems to be safe and effective for recalcitrant facial warts and may save the patient from embarrassment and stress with minimal cost and time. Further larger studies are needed to assess the efficacy of this modality of treatment for patients with numerous facial warts.

Disclosure
The authors declare no conflicts of interest and certify that both the patients gave consent for their images and clinical information to be published, after being informed that their names would not be published but anonymity could not be guaranteed.

Acknowledgements
We thank both the patients for giving their consent to publish their cases.

REFERENCES
1. Gonçalves MA, Donadi EA. Immune cellular response to HPV: current concepts. Braz J Infect Dis 2004 Feb;8(1):1-9.
2. Lipke MM. An armamentarium of wart treatments. Clin Med Res 2006 Dec;4(4):273-293.
3. Monk BJ, Tewari KS. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol 2007 Nov;107(2)(Suppl 1):S6-S13.
4. Bologna JL, Jorizzo JL, Schaffer JV, Callen JP, Cerroni L, Heymann WR, et al. Dermatology. 3rd ed. Elsevier Health Sciences; 2012. p. 1307.
5. Leung L. Recalcitrant nongenital warts. Aust Fam Physician 2011 Jan-Feb;40(1-2):40-42.
6. Ciconte A, Campbell J, Tabrizi S, Garland S, Marks R. Warts are not merely blemishes on the skin: a study on the
morbidity associated with having viral cutaneous warts. Australas J Dermatol 2003 Aug;44(3):169-173.

7. Nofal A, Nofal E, Yosef A, Nofal H. Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach. Int J Dermatol 2015 Jun;54(6):667-671.

8. Maranda EL, Lim VM, Nguyen AH, Nouri K. Laser and light therapy for facial warts: a systematic review. J Eur Acad Dermatol Venereol 2016 Oct;30(10):1700-1707.

9. Sidharth S, Rahul A, Rashmi S. Cosmetic warts: pseudo-koeberization of warts after cosmetic procedures for hair removal. J Clin Aesthet Dermatol 2013 Jul;8(7):52-56.

10. Khan Durani B, Jappe U. Successful treatment of facial plane warts with imiquimod. Br J Dermatol 2002 Nov;147(5):1018.

11. Schwab RA, Elston DM. Topical imiquimod for recalcitrant facial flat warts. Cutis 2000 Mar;65(3):160-162.

12. Clouth A, Schöfer H. Treatment of recalcitrant facial verrucae vulgarres with sin catechins (green tea catechins) ointment. J Eur Acad Dermatol Venereol 2015 Jan;29(1):178-179.

13. Kartal Durmazlar SP, Atacan D, Eskilghu F. Cantharidin treatment for recalcitrant facial flat warts: a preliminary study. J Dermatolog Treat 2009;20(2):114-119.

14. Olguin-García MG, Jurado-Santa Cruz E, Peralta-Pedrero ML, Morales-Sánchez MA. A double-blind, randomized, placebo-controlled trial of oral isotretinoin in the treatment of recalcitrant facial flat warts. J Dermatolog Treat 2015 Feb;26(1):78-82.

15. Al-Hamamy HR, Salman HA, Abdul sattar NA. Treatment of plane warts with a low-dose oral isotretinoin. ISRN Dermatol 2012;2012:163929.

16. Kenton-Smith J, Tan ST. Pulsed dye laser therapy for viral warts. Br J Plast Surg 1999 Oct;52(7):554-558.

17. Yang C, Liu S, Yang S. Treatment of facial recalcitrant verruca vulgaris with holmium: YAG laser: an update. J Cosmet Laser Ther 2013 Feb;15(1):39-41.

18. Al-Taweel AA, Salem R, Allam A. Intralesional 2% zinc sulfate solution for plane warts: a case report. Dermatol Ther 2019 Jan;32(1):e12761.

19. Salman S, Ahmed MS, Ibrahim AM, Mattar OM, El-Shirbiny H, Sarsik S, et al. Intralesional immunotherapy for the treatment of warts: A network meta-analysis. J Am Acad Dermatol 2019 Apr;80(4):922-930.e4.

20. Clifton MM, Johnson SM, Roberson PK, Kincannon J, Horn TD. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol 2003 May-Jun;20(3):268-271.

21. Signore RJ. Candida albicans intralesional injection immunotherapy of warts. Cutis 2002 Sep;70(3):185-192.

22. Awal G, Kaur S. Therapeutic outcome of intralesional immunotherapy in cutaneous warts using the mumps, measles, and rubella vaccine: a randomized, placebo-controlled trial. J Clin Aesthet Dermatol 2018 May;11(5):15-20.